Skip to main content

Table 4 Effect of IPTsc on clinical malaria during the intervention period

From: Efficacy and safety of intermittent preventive treatment for malaria in schoolchildren: a systematic review

  Study site Drug regime No of children Incidence rate per 1000 PYAR PE (95 % CI)
Dicko [23] Kambila SP (bimonthly) 2.7a 40.1 (17.9–56.4)
   Control 4.5a
Barger Barger [25] Kollé SP + AS 91 488 67 (42–98)
   AQ + AS 97 782 47 (32–67)
   Placebo 96 1463
Nankabirwa [27] Tororo DP (monthly) 236 0.01 97 (87–98)
   DP (three and five monthly) 234 0.34 0.00
   Placebo 243 0.34
  1. PE protective effect, No number, SP sulfadoxine-pyrimethamine, SP + AQ sulfadoxine-pyrimethamine plus amodiaquine, SP + AS sulfadoxine-pyrimethamine plus artesunate, DP dihydroartemisinin-piperaquine, data not available, PYAR person-year at risk
  2. a5–10 years sub-group